Drugs / ALDUMASTAT
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04137341 | Oct → Dec 2019 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04136327 | Sep → Oct 2019 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03311009 | May → Oct 2017 | osteoarthritis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03143725 | Apr → Jun 2017 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02851485 | Jul 2016 | osteoarthritis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02612246 | Nov 2015 → Apr 2016 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03595618 | Aug 2018 → Jul 2020 | osteoarthritis | Lakefront Biotherapeutics NV | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2018-04-27 | Lakefront Biotherapeutics NV | Results Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018 lakefrontbio.com ↗
Galapagos NV (Euronext & NASDAQ: GLPG) presents preclinical results showing broad beneficial effects on cartilage and bone with GLPG1972 in an osteoarthritis (OA) rat model at the Osteoarthritis Research Society International (OARSI) World Congress today in Liverpool, UK. |
| 2018-01-07 | Lakefront Biotherapeutics NV | Results Positive topline results with GLPG1972 in osteoarthritis patients lakefrontbio.com ↗
Galapagos NV (Euronext & NASDAQ: GLPG) reports positive preliminary topline results with a Phase 1b study in osteoarthritis (OA) patients in the United States. |
| 2017-06-20 | Lakefront Biotherapeutics NV | Regulatory Galapagos’ R&D Update 2017: rapidly advancing our product candidates lakefrontbio.com ↗
Galapagos opened an Investigational New Drug (IND) dossier with the FDA for ‘1972 and achieved first dosing in a Phase 1b patient trial in the US. |
| 2017-04-29 | Lakefront Biotherapeutics NV | Results Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI lakefrontbio.com ↗
At the OARSI 2017 World Congress, Galapagos presents pre-clinical pharmacology data with GLPG1972 showing cartilage protection in both rodent and human explant assays. |
| 2016-06-15 | Lakefront Biotherapeutics NV | Results Galapagos’ R&D Update 2016 lakefrontbio.com ↗
GLPG1972 strongly reduces OA cartilage breakdown biomarker within two weeks |
All press releases naming this drug 7 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALDUMASTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650334 ↗ |
| Known as | G-504572 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650334 ↗ |
| Known as | GLPG1972 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04136327 ↗ |
| Known as | S201086 | “Participants were randomized 1:1:1:1 to once-daily oral S201086/GLPG1972 75, 150 or 300 mg, or placebo for 52 weeks.” PMID 37059327 ↗ Apr 2023 |
| Action | Inhibit | “ADAMTS5 inhibitor” CHEMBL4650334 ↗ |
| Modality | Small molecule | “We describe the discovery of GLPG1972/S201086, a potent and selective ADAMTS-5 inhibitor obtained by optimization of a promising hydantoin series following an HTS.” PMID 33719441 ↗ Mar 2021 |
| Route | Oral | “single ascending oral doses of GLPG1972” NCT02612246 ↗ |
| Target | ADAMTS5 | “ADAMTS5 inhibitor” CHEMBL4650334 ↗ |